OXFORD, ENGLAND, April 5, 2024 (Newswire.com) –
GENinCode Plc (www.genincode.com) Polygenics, a company focused on the prevention of cardiovascular disease and ovarian cancer, today announced the publication of a study by the American Journal of Preventive Cardiology.Polygenic risk and development of heart disease in a large multiethnic cohort^1..

The Kaiser Permanente Research Division study enrolled more than 63,000 adults without a history of coronary heart disease (CHD) from the Kaiser Permanente Northern California Genetic Epidemiology Resource for Adult Health and Aging (GERA) multiethnic cohort. investigated. The GERA cohort followed members for an average of 14 years using CARDIO inCode-Score.® Assess polygenic risk for CHD and incidence of future CHD risk.

In this study, CARDIO inCode-Score® Identify individuals at highest risk of CHD. These people should be prioritized for lifestyle advice and appropriate therapeutic interventions that will be most effective. Previous data using CARDIO inCode-Score® showed that for people at high genetic risk, a favorable lifestyle was associated with a 52% lower incidence of CHD compared with an unfavorable lifestyle. CHD “events” include non-fatal AMI, angina or coronary atherosclerosis, coronary revascularization (coronary bypass or percutaneous intervention), or CHD death. This study highlights the need for a “polygenic risk score” lifetime risk assessment combined with traditional clinical risk assessment to optimize preventive treatment strategies to reduce future CHD risk.

Polygenic risk assessment can be performed in younger people before the onset of traditional clinical risk factors (hypertension, diabetes, etc.) and can be combined with traditional risk scoring in older adults. In this way, clinicians will be able to better identify patients who are most likely to benefit from lifestyle and therapeutic interventions.

GENinCode begins commercializing CARDIO inCode-Score® (or CIC-SCORE) in conjunction with leading medical institutions to improve estimates of an individual’s lifetime risk of heart attack. CIC scores are provided by GENinCode CLIA and CAP certified lab located in Irvine, California.

GENinCode submitted CIC scores.Also’ We submitted a medical device to the FDA late last year. The Company is in the process of filing for FDA approval of the CIC-SCORE medical device.

GENinCode will be attending the annual ACC Conference in Atlanta this weekend, April 6-8. For more information or to arrange a meeting, please email us: us@genincode.com

https://www.sciencedirect.com/science/article/pii/S2666667724000291

Source: GENinCode PLC